All In Biotech

Drug Trial Radar · NCT02146430

Treatment of Pain Associated With Fibromyalgia

A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia

Last checked: Nov 20, 2026Latest source record: Nov 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,293 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,293

Actual

Start

Oct 27, 2014

Primary completion

Jul 14, 2016

Study completion Jul 14, 2016

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Syneos Health
First posted
May 23, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in subjects receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the participant that best describes his or her worst pain over the previous 24 hours.

Conditions

  • Pain Associated With Fibromyalgia

Interventions

  • DS-5565Drug

    DS-5565 15 mg tablet for oral administration

  • PregabalinDrug

    Pregabalin 150 mg capsule for oral administration

  • Placebo tabletDrug

    Placebo tablet (matching DS-5565) for oral administration

  • Placebo capsuleDrug

    Placebo capsule (matching pregabalin) for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Weekly Average Daily Pain Score (ADPS) at Week 13 in Participants Receiving DS-5565, Pregabalin, PlaceboTime frame: Baseline up to Week 13 postdose

Locations

165 sites in 11 countries. Site status is shown where the registry gives one.

  • Site not named

    Glendale, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Anaheim, California

  • Site not named

    Beverly Hills, California

  • Site not named

    Los Alamitos, California

  • Site not named

    Newport Beach, California

  • Site not named

    Oakland, California

  • Site not named

    Rancho Mirage, California

  • Site not named

    Roseville, California

  • Site not named

    San Diego, California

  • Site not named

    Sherman Oaks, California

  • Site not named

    Torrance, California

  • Site not named

    Tustin, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Cromwell, Connecticut

  • Site not named

    Danbury, Connecticut

  • Site not named

    Boynton Beach, Florida

  • Site not named

    Bradenton, Florida

  • Site not named

    Brooksville, Florida

  • Site not named

    Coral Springs, Florida

  • Site not named

    Gainesville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Lakeland, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Port Orange, Florida

  • Site not named

    Royal Palm Beach, Florida

  • Site not named

    Sanford, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Savannah, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Elwood, Indiana

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Newton, Kansas

  • Site not named

    Wichita, Kansas

  • Site not named

    Wheaton, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Fall River, Massachusetts

Showing 40 of 165 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.